Trexquant Investment LP Crinetics Pharmaceuticals, Inc. Transaction History

Trexquant Investment LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$25.62 - $37.07 $390,269 - $564,687	15,233 Added 205.55%	22,644 $805,000
Q3 2023 Nov 13, 2023	BUY	$15.97 - $30.59 $118,353 - $226,702	7,411 New	7,411 $220,000
Q1 2023 May 15, 2023	BUY	$15.31 - $21.1 $194,482 - $268,033	12,703 New	12,703 $204,000
Q3 2022 Nov 14, 2022	BUY	$18.11 - $22.37 $190,028 - $234,728	10,493 Added 74.86%	24,509 $481,000
Q2 2022 Aug 11, 2022	BUY	$16.49 - $27.64 $231,123 - $387,402	14,016 New	14,016 $261,000

220

75.8M

631K

749K

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $2.41B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

Stay updated on Trexquant Investment LP with notifications on news.